PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C
T Goldmann, N Overlack, U Wolfrum… - Human gene …, 2011 - liebertpub.com
T Goldmann, N Overlack, U Wolfrum, K Nagel-Wolfrum
Human gene therapy, 2011•liebertpub.comWe investigated the therapeutic potential of the premature termination codon (PTC)
readthrough-inducing drug PTC124 in treating the retinal phenotype of Usher syndrome,
caused by a nonsense mutation in the USH1C gene. Applications in cell culture, organotypic
retina cultures, and mice in vivo revealed significant readthrough and the recovery of protein
function. In comparison with other readthrough drugs, namely the clinically approved
readthrough-inducing aminoglycoside gentamicin, PTC124 exhibits significant better retinal …
readthrough-inducing drug PTC124 in treating the retinal phenotype of Usher syndrome,
caused by a nonsense mutation in the USH1C gene. Applications in cell culture, organotypic
retina cultures, and mice in vivo revealed significant readthrough and the recovery of protein
function. In comparison with other readthrough drugs, namely the clinically approved
readthrough-inducing aminoglycoside gentamicin, PTC124 exhibits significant better retinal …
Abstract
We investigated the therapeutic potential of the premature termination codon (PTC) readthrough-inducing drug PTC124 in treating the retinal phenotype of Usher syndrome, caused by a nonsense mutation in the USH1C gene. Applications in cell culture, organotypic retina cultures, and mice in vivo revealed significant readthrough and the recovery of protein function. In comparison with other readthrough drugs, namely the clinically approved readthrough-inducing aminoglycoside gentamicin, PTC124 exhibits significant better retinal biocompatibility. Its high readthrough efficiency in combination with excellent biocompatibility makes PTC124 a promising therapeutic agent for PTCs in USH1C, as well as other ocular and nonocular genetic diseases.
Mary Ann Liebert